-
1 Comment
ORIENT BIO Inc is currently in a long term downtrend where the price is trading 19.9% below its 200 day moving average.
From a valuation standpoint, the stock is 59.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.5.
ORIENT BIO Inc's total revenue rose by 35.1% to $14B since the same quarter in the previous year.
Its net income has increased by 556.6% to $4B since the same quarter in the previous year.
Finally, its free cash flow grew by 126.2% to $803M since the same quarter in the previous year.
Based on the above factors, ORIENT BIO Inc gets an overall score of 4/5.
Exchange | KO |
---|---|
CurrencyCode | KRW |
ISIN | KR7002630002 |
Sector | Healthcare |
Industry | Biotechnology |
Market Cap | 163B |
---|---|
PE Ratio | None |
Target Price | None |
Beta | 0.8 |
Dividend Yield | None |
ORIENT BIO Inc. operates in the bio-industry in South Korea. It produces laboratory animals; and offers various equipment for research environment. The company was formerly known as Orient Co., Ltd. and changed its name to ORIENT BIO Inc. in 2005. ORIENT BIO Inc. was founded in 1959 and is based in Seongnam-si, South Korea.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 002630.KO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025